Atea Pharmaceuticals, Inc. (AVIR) Stock

Atea Pharmaceuticals, Inc. (AVIR) is a Healthcare stock trading at $5.42 (as of 2026-08-21), with a market capitalization of $434.71M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for patients with viral infections. Its pipeline includes AT-527 for COVID-19 and other antiviral candidates such as AT-752, AT-777, and AT-787, alongside AT-281 and ruzasvir for chronic hepatitis C, with a Merck license related to ruzasvir.

Valuation — source: SEC EDGAR (first-party)
Price$5.42
Market Cap$434.71M
Price / Book2.13
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$351.37M
Net Margin34.5%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($64.30M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJean-Pierre Sommadossi
Employees56
CountryUS
IPO Date2020-10-30

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Rezolute, Inc. (RZLT)
  • Relmada Therapeutics, Inc. (RLMD)
  • Puma Biotechnology, Inc. (PBYI)
  • Benitec Biopharma Inc. (BNTC)
  • BioAge Labs, Inc. (BIOA)
  • Foghorn Therapeutics Inc. (FHTX)
  • Enanta Pharmaceuticals, Inc. (ENTA)
  • Rocket Pharmaceuticals, Inc. (RCKT)
AVIR earnings history · AVIR institutional & insider holders · AVIR KPIs & operating metrics · AVIR financials · AVIR investor presentations & press releases · AVIR SEC filings · AVIR peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.